Spur Therapeutics News and Activities

Spur Therapeutics is owned by Syncona.

Syncona is one of the...

• FTSE 350;
• TOB Iconic 10,000.

Syncona is a company listed under the stock ticker SYNC (GB).

Syncona has a direct presence in 3 countries.

Syncona has 11 subsidiaries including Anaveon, Autolus Therapeutics and Beacon Therapeutics.

They are in:

• Biotechnology83%
• Holding8%
• Other8%

Acquisition, funding and merger involving Syncona.

• Freeline Therapeutics will change its company name to Spur Therapeutics on Jun 17, 2024. (posted on June 18 2024).

View the org chart displaying its 18 main executives

Most searched biographies at Spur Therapeutics

• Michael Parini, Chief Executive Officer and Executive Director
• Chris Hollowood, Chairman of the Board
• James Davies, Director, Corporate Development and Strategy, Chief ...

Popular executive movements at Spur Therapeutics

• Dan Wolf, Senior Medical Director, Genetic Medicines, has left the company  (posted on May 20 2026).
• Tiffany Lutz who was Senior Manager, Clinical Operations, becomes Senior Clinical Project Manager  (posted on May 20 2026).
• Simon Flynn who was Director, Medical Sciences, becomes Senior Director, Medical Sciences  (posted on May 20 2026).

Create your alert
to follow the executive moves at Spur Therapeutics.

Syncona has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Spur Therapeutics

• Spur Therapeutics Presents Clinical Insights on Bone Disease Impact of FLT201 in Adults with Gaucher Disease Type 1
• Spur Therapeutics To Present New Clinical Data on FLT201 for Gaucher Disease during the IWGGD 2026 Symposium
• Spur Therapeutics Presents New Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at 22nd Annual WORLDSymposium™
• Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium™
• Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress
• Spur Therapeutics to Present New Clinical Data on Its Gene Therapy Candidate in Gaucher Disease at Upcoming ESGCT Annual Congress
• Spur Therapeutics Presents Positive New Preclinical Data on Its Gene Therapy Candidate for GBA1 Parkinson’s Disease at 2025 GBA1 Meeting
• Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for FLT201, its Clinical-Stage Gene Therapy Candidate in Gaucher Disease
• Spur Therapeutics Announces Oral and Poster Presentations Highlighting Data from Clinical and Preclinical Programs at Upcoming ASGCT Annual Meeting
• Spur Therapeutics to Participate in Citizens JMP 2025 Life Sciences Conference
• View more press releases Close

Social media about Spur Therapeutics

• Spur Therapeutics on Wikipedia, Google News & Yahoo Finance
• Spur Therapeutics on LinkedIn, X (Twitter) & YouTube